MedPath

Biperiden

Generic Name
Biperiden
Drug Type
Small Molecule
Chemical Formula
C21H29NO
CAS Number
514-65-8
Unique Ingredient Identifier
0FRP6G56LD
Background

A muscarinic antagonist that has effects in both the central and peripheral nervous systems. It has been used in the treatment of arteriosclerotic, idiopathic, and postencephalitic parkinsonism. It has also been used to alleviate extrapyramidal symptoms induced by phenothiazine derivatives and reserpine.

Indication

用于治疗震颤麻痹及药物引起的锥体外系症状。

Associated Conditions
Extrapyramidal Symptoms, Extrapyramidal disorder caused by neuroleptic drugs without Tardive dyskinesia, Parkinson's Disease (PD), Poisoning caused by Nicotine, Poisoning caused by organophosphorus pesticides
Clinical Trials
Related News

Biperiden Trial for Epilepsy Prevention

Phase 3
Recruiting
Conditions
Brain Injury Traumatic Moderate
Brain Injury Traumatic Severe
Post Traumatic Epilepsy
Interventions
Other: Placebo
First Posted Date
2021-06-30
Last Posted Date
2024-03-26
Lead Sponsor
Hospital Sirio-Libanes
Target Recruit Count
312
Registration Number
NCT04945213
Locations
🇧🇷

Hospital das Clínicas da Faculdade de Medicina da Universidade de Ribeirão Preto, Ribeirão Preto, SP, Brazil

🇧🇷

Hospital São Vicente de Paulo, Passo Fundo, RS, Brazil

🇧🇷

Hospital São Paulo, Universidade Federal de São Paulo, São Paulo, Brazil

and more 7 locations

Pharmacovigilance in Gerontopsychiatric Patients

Phase 3
Terminated
Conditions
Dementia
Depression
Schizophrenia
Psychosomatic Disorders
Anxiety Disorders
Interventions
First Posted Date
2015-03-02
Last Posted Date
2018-02-28
Lead Sponsor
Hannover Medical School
Target Recruit Count
407
Registration Number
NCT02374567
Locations
🇩🇪

Bezirkskrankenhaus Augsburg, Augsburg, Germany

🇩🇪

Krankenhaus Hedwigshöhe, Berlin, Germany

🇩🇪

Hannover Medical School, Hannover, Germany

and more 2 locations

Cocaine/Crack and Reduction of Compulsion With Biperiden

Phase 3
Completed
Conditions
Cocaine Dependence
Interventions
Drug: Placebo
First Posted Date
2010-12-01
Last Posted Date
2020-10-14
Lead Sponsor
Federal University of São Paulo
Target Recruit Count
111
Registration Number
NCT01251393
Locations
🇧🇷

UDED - Drug Dependence Unit, São Paulo, Brazil

Use of Biperiden for the Prevention of Post-traumatic Epilepsy

Phase 3
Terminated
Conditions
Traumatic Brain Injury
Interventions
Drug: Placebo
First Posted Date
2010-01-13
Last Posted Date
2023-01-31
Lead Sponsor
Federal University of São Paulo
Target Recruit Count
123
Registration Number
NCT01048138
Locations
🇧🇷

Federal University of São Paulo, Sao Paulo, Brazil

Efficacy of Caffeine, With and Without Biperiden, as a Maintenance Treatment for Cocaine Dependence

Phase 4
Conditions
Cocaine Dependence
Interventions
Drug: Placebo
First Posted Date
2007-07-02
Last Posted Date
2010-05-27
Lead Sponsor
Hospital Universitari Vall d'Hebron Research Institute
Target Recruit Count
108
Registration Number
NCT00495183
Locations
🇪🇸

Hospital Universitari Vall d'Hebron, Barcelona, Catalonia, Spain

Efficacy of Caffeine, With and Without Biperiden, in the Detoxification of Cocaine Dependent Patients

Phase 2
Completed
Conditions
Cocaine Related Disorders
Interventions
Drug: Placebo
First Posted Date
2007-07-02
Last Posted Date
2012-03-01
Lead Sponsor
Hospital Universitari Vall d'Hebron Research Institute
Target Recruit Count
85
Registration Number
NCT00495092
Locations
🇪🇸

Hospital Universitari Vall d'Hebron, Barcelona, Catalonia, Spain

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy